Skip to main content
Caplight Logo









Nuage Therapeutics

Nuage Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttps://nuagetx.com/

Last Round

Grant

Dec 2, 2025

Total Funding Raised

$18.26M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nuage Therapeutics is a biotechnology company that develops drugs designed to target intrinsically disordered proteins for the treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

intrinsically disordered proteinsIDPsdrug discovery platformundruggable targetssmall molecule drugsbiomolecular condensatesoncology therapeuticsdrug developmentpharma partnershipsprotein modulationbiophysics screeningprostate cancersmall-cell lung cancer

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nuage Therapeutics Comparables

Compare Nuage Therapeutics with similar companies based on industry and business-model similarity.

Nuage Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kodiform Therapeutics
87%
Nereid
86%
Transition Bio, Inc.
85%

Nuage Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 2, 2025
SeedMay 26, 2025
SeedJun 20, 2023

Key People

Founding team and executive leadership

Mateusz Biesaga

Chief Technology Officer, Scientific Co-Founder

Founding Team

Stuart Hughes

Chief Executive Officer

Executive Team

Pilar Casado Garcia

CFO

Executive Team

Nuage Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 20, 2026

    Monthly visitors grew 98% MoM, reaching 1.1K.

  • Dec 2, 2025

    $3.1M grant received from Agencia Estatal de Investigación.

Nuage Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nuage Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nuage Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range22
Year Founded2021
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?